Quanterix Announces CEO Transition to Drive Growth
TipRanks (Thu, 8-Jan 5:19 PM ET)
Quanterix appoints new president and CEO
Seeking Alpha News (Thu, 8-Jan 4:35 PM ET)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Business Wire (Thu, 8-Jan 4:30 PM ET)
TipRanks (Thu, 8-Jan 9:50 AM ET)
QTRX: Landmark Alzheimer’s Study Reveals Powerful Insights with 11,000+ Sample Analysis
Market Chameleon (Mon, 22-Dec 5:05 AM ET)
Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence
Business Wire (Mon, 22-Dec 7:30 AM ET)
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
Business Wire (Thu, 20-Nov 4:15 PM ET)
Business Wire (Mon, 17-Nov 5:30 PM ET)
Quanterix Releases Financial Results for the Third Quarter of 2025
Business Wire (Mon, 10-Nov 4:01 PM ET)
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
Business Wire (Mon, 3-Nov 7:00 AM ET)
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Quanterix trades on the NASDAQ stock market under the symbol QTRX.
As of January 8, 2026, QTRX stock price declined to $6.51 with 293,551 million shares trading.
QTRX has a beta of 0.76, meaning it tends to be less sensitive to market movements. QTRX has a correlation of 0.04 to the broad based SPY ETF.
QTRX has a market cap of $304.09 million. This is considered a Small Cap stock.
Last quarter Quanterix reported $40 million in Revenue and -$.35 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.06.
In the last 3 years, QTRX traded as high as $29.70 and as low as $4.05.
The top ETF exchange traded funds that QTRX belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
QTRX has underperformed the market in the last year with a price return of -44.8% while the SPY ETF gained +18.4%. However, in the short term, QTRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.0% vs +3.3% return in SPY. But in the last 2 weeks, QTRX shares have been beat by the market, returning -1.7% compared to an SPY return of -0.1%.
QTRX support price is $6.44 and resistance is $6.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTRX shares will trade within this expected range on the day.